Results 131 to 140 of about 11,862,011 (403)

Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)

open access: yesJournal of Dermatological Treatment
Purpose Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 ...
Luigi Gargiulo   +40 more
doaj   +1 more source

Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors

open access: yesDermatology and Therapy, 2020
Introduction Hidradenitis suppurativa (HS) is a chronic, debilitating, and inflammatory skin disease. The epidemiology of HS varies greatly, with an estimated prevalence ranging from 0.03% to 4% worldwide.
Andreas Pinter   +6 more
doaj   +1 more source

Paradoxical Activation of Entheseal Myeloid Cells by JAK1 and Tyk2 Inhibitors via Interleukin‐10 Antagonism

open access: yesArthritis &Rheumatology, EarlyView.
Objective JAK inhibition (JAKi) is effective in seronegative spondyloarthropathy (SpA) spectrum disorders, but Tyk2 inhibition failed in SpA spectrum ulcerative colitis, and tofacitinib showed minimal benefit in Crohn disease, which highlights the complex role for JAK/STAT signaling in different inflammatory processes.
Sami Giryes   +14 more
wiley   +1 more source

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. [PDF]

open access: yes, 2019
Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs)
Beck, Kristen M   +4 more
core  

Current Perspectives on Psoriasis and Its Therapeutic Approaches: A Comprehensive Review

open access: yesJournal of Education, Health and Sport
Psoriasis is a chronic inflammatory skin disorder characterized by an accelerated keratinocyte cell cycle, leading to the formation of scaly plaques.
Daria Oleksy   +9 more
doaj   +1 more source

Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis

open access: yesJournal of Immunology, 2018
Psoriasis vulgaris is a common, heterogeneous, chronic inflammatory skin disease characterized by thickened, red, scaly plaques and systemic inflammation.
J. Hawkes, B. Yan, T. Chan, J. Krueger
semanticscholar   +1 more source

Mucosal‐associated invariant T cells in rheumatic diseases.

open access: yesArthritis &Rheumatology, Accepted Article.
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor (TCR) and restriction by the MHC class I‐related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines. Upon activation, MAIT cells rapidly produce pro‐inflammatory cytokines,
Manon Lesturgie‐Talarek   +7 more
wiley   +1 more source

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3) [PDF]

open access: yes, 2018
Background: The study aimed to assess 52-week efficacy and safety of secukinumab self-administration by autoinjector in patients with active psoriatic arthritis (PsA) in the FUTURE 3 study (ClinicalTrials.gov NCT01989468).
Andersson, Mats   +11 more
core   +1 more source

Loss of TRIM21 drives UVB‐induced systemic inflammation by regulating DNA‐sensing pathways

open access: yesArthritis &Rheumatology, Accepted Article.
Background Patients with systemic lupus erythematosus (SLE) experience photosensitivity, with exposure to ultraviolet light B (UVB) driving lupus flares and triggering symptoms like joint pain, fatigue, and cutaneous lesions. Although the mechanism(s) linking UVB exposure to systemic effects are unclear, type I interferons (IFNs) are known to play a ...
Gantsetseg Tumurkhuu   +17 more
wiley   +1 more source

The pathological role of Wnt5a in psoriasis and psoriatic arthritis. [PDF]

open access: yes, 2019
Psoriasis (PsO) is a chronic inflammatory skin disease with both local and systemic components. PsO-associated arthritis, known as psoriatic arthritis (PsA), develops in approximately 13%-25% of PsO patients.
Li, Zhengxiao   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy